Clinical Trials - Carolina Blood and Cancer Care Associates

Clinical trials are essential in the medical field as they allow for the evolution of the standards of care. Within the oncology specialty, these efforts are dedicated to advancing the methods of cancer prevention, detection, and treatment. Currently, our list of ongoing trials include:

Sponsor : Amgen

Protocol No:

20170758

Title:

A Prospectitve Observational Study to Estimate the Incidence of Febrile Neutropenia (FN) Among Subjects With Non-myeloid Malignancies at High Risk for FN and Receiving Neulasta (pegfilgrastim) Onpro kit or Other Physician Choice Options for Prophylaxis of FN

Diagnosis Requirements:

breast cancer, lung cancer, non-Hodgkin’s lymphoma, or prostate cancer

Ask your doctor about this trial if:

You are beginning a new chemotherapy regimen soon

Sponsor : Aptose Biosciences

Protocol No:

APTO-CG-806-01

Title:

A Phase 1 a/b trial to evaluate the safety and tolerability of CG-806 in patients with CLL/SLL or Non-Hodgkin’s Lymphomas

Diagnosis Requirements:

Non-Hodgkin’s lymphoma or chronic lymphocytic lymphoma

Ask your doctor about this trial if:

You have one of these conditions, have been in remission, and are now needing new treatment

Note: Involves investigational product

Sponsor : Aptose Biosciences

Protocol No:

APTO-CG-806-01

Title:

A Phase 1 a/b trial to evaluate the safety and tolerability of CG-806 in patients with CLL/SLL or Non-Hodgkin’s Lymphomas

Diagnosis Requirements:

Non-Hodgkin’s lymphoma or chronic lymphocytic lymphoma

Ask your doctor about this trial if:

You have one of these conditions, have been in remission, and are now needing new treatment

Note: Involves investigational product

Sponsor : Celgene Corporation

Protocol No:

ACE-536-MDS-002

Title:

A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) versus Epoetin alfa for the Treatment of Anemia due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in ESA Naïve Subjects who require Red Blood Cell Transfusions.

Diagnosis Requirements:

A Phase 1 a/b trial to evaluate the safety and tolerability of CG-806 in patients with CLL/SLL or Non-Hodgkin’s Lymphomas

Ask your doctor about this trial if:

You receive red-blood cell transfusions, but have not received any EPO stimulating agents (i.e. Procrit)

Note: Involves investigational product

Sponsor: Paradigm Diagnostics Registry

Protocol No:

20170357

Title:

A Prospective Registry Study to Evaluate the Efficacy of Precision Molecular Testing in the Treatment of Advanced Solid Tumors

Note: Testing is done as part of standard of care. Once testing is completed, patient may be approached about enrolling in the voluntary registry

Please contact the Carolina Blood and Cancer Care Associates Clinical Research team with any questions, or if interested in any of these studies at (803)-329-7772 All clinical studies and trials run by Carolina Blood and Cancer Care Associates can be found at clinicaltrials.gov